drugset / Trial / NCT04622891
Clarithromycin Versus Azithromycin in Treatment of Mild COVID-19 Infection
RandomizedParallel-groupDouble-blindTreatment
Summary
The current study was conducted at Qena Governorate, Egypt, during the period from May 2020, to July 2020. The study included 305 COVID-19 cases diagnosed by PCR, patients were randomly assigned to one of three study limps, Azithromycin 500 mg/24 h for 7 days, Clarithromycin 500 /12 h for 7 days, or a control group with no antibiotics, All three groups received only symptomatic treatment for control of fever and cough
Timeline
- Start
- 2020-04-01
- Primary completion
- 2020-07-30
- Completion
- 2020-07-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Azithromycin | Small molecule | 500 mg | — |
| Subject | Clarithromycin | Small molecule | 500 mg | — |